12,618 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Bought by Baader Bank Aktiengesellschaft

Key Points

• Baader Bank Aktiengesellschaft acquired 12,618 shares of TG Therapeutics, Inc. for approximately $492,000 in the 1st quarter, highlighting growing institutional interest in the biopharmaceutical company.
• According to analysts, TG Therapeutics has been upgraded to a "hold" rating by Goldman Sachs with a price target of $37.00, while the average target price is set at $43.80.
• TG Therapeutics reported a revenue increase of 90.4% year-over-year, with earnings missing the consensus estimate, indicating mixed financial performance amid growth opportunities.

Baader Bank Aktiengesellschaft purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 12,618 shares of the biopharmaceutical company's stock, valued at approximately $492,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Norges Bank purchased a new stake in TG Therapeutics during the 4th quarter worth approximately $12,085,000. Allspring Global Investments Holdings LLC increased its holdings in TG Therapeutics by 54.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 23,775 shares of the biopharmaceutical company's stock worth $898,000 after purchasing an additional 8,338 shares during the last quarter. New York State Teachers Retirement System increased its holdings in TG Therapeutics by 175.0% during the 1st quarter. New York State Teachers Retirement System now owns 120,364 shares of the biopharmaceutical company's stock worth $4,746,000 after purchasing an additional 76,600 shares during the last quarter. Crossmark Global Holdings Inc. purchased a new stake in TG Therapeutics during the 1st quarter worth approximately $226,000. Finally, GAMMA Investing LLC increased its holdings in TG Therapeutics by 77.7% during the 1st quarter. GAMMA Investing LLC now owns 4,543 shares of the biopharmaceutical company's stock worth $179,000 after purchasing an additional 1,986 shares during the last quarter. 58.58% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group upgraded TG Therapeutics to a "hold" rating and set a $37.00 price objective on the stock in a report on Thursday, July 10th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $43.80.

TG Therapeutics Stock Performance

Shares of NASDAQ TGTX traded down $5.15 during trading on Monday, reaching $29.87. The stock had a trading volume of 8,071,553 shares, compared to its average volume of 2,448,121. TG Therapeutics, Inc. has a one year low of $16.65 and a one year high of $46.48. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.04 and a current ratio of 4.02. The stock has a market cap of $4.74 billion, a PE ratio of 124.36 and a beta of 1.95. The firm's 50 day moving average price is $36.83 and its two-hundred day moving average price is $36.10.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). TG Therapeutics had a net margin of 10.13% and a return on equity of 18.88%. The firm had revenue of $141.15 million during the quarter, compared to the consensus estimate of $147.76 million. During the same quarter last year, the firm posted $0.04 earnings per share. TG Therapeutics's revenue was up 92.1% compared to the same quarter last year. On average, research analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Yann Echelard sold 10,000 shares of the company's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $36.94, for a total transaction of $369,400.00. Following the completion of the transaction, the director directly owned 228,816 shares in the company, valued at $8,452,463.04. This represents a 4.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.64% of the stock is currently owned by insiders.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.